Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute coronary syndromes

Targeting inflammation—what has the VISTA-16 trial taught us?

Nature Reviews Cardiology volume 11, pages 130–132 (2014)Cite this article

Subjects

The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm. Despite these discouraging results, therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: sPLA2 has been hypothesized to promote atherogenesis through several mechanisms.

References

  1. Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA http://dx.doi.org/10.1001/jama.2013.282836.

  2. Mallat, Z., Lambeau, G. & Tedgui, A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 122, 2183–2200 (2010).

    Article  Google Scholar 

  3. Rosenson, R. S. & Hurt-Camejo, E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur. Heart J. 33, 2899–2909 (2012).

    Article  CAS  Google Scholar 

  4. Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. & Lusis, A. J. The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623–629 (2009).

    Article  CAS  Google Scholar 

  5. Fujioka, D. et al. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation 117, 2977–2985 (2008).

    Article  CAS  Google Scholar 

  6. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).

    Article  CAS  Google Scholar 

  7. Schwartz, G. G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711–1718 (2001).

    Article  CAS  Google Scholar 

  8. Dzavik, V. et al. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. Circulation 122, 2411–2418 (2010).

    Article  CAS  Google Scholar 

  9. Holmes, M. V. et al. Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study. J. Am. Coll. Cardiol. 62, 1966–1976 (2013).

    Article  CAS  Google Scholar 

  10. GlaxoSmithKline. GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease [online], (2013).

Download references

Author information

Authors and Affiliations

  1. TIMI Study Group, Brigham and Women's Hospital, 350 Longwood Avenue, 1st Floor, Boston, 02115, MA, USA

    Michelle L. O'Donoghue

Authors
  1. Michelle L. O'Donoghue
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Michelle L. O'Donoghue.

Ethics declarations

Competing interests

M. L. O'Donoghue has acted as a consultant for Aegerion, and has received grants/research support from AstraZeneca, Genzyme, and GlaxoSmithKline.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Donoghue, M. Targeting inflammation—what has the VISTA-16 trial taught us?. Nat Rev Cardiol 11, 130–132 (2014). https://doi.org/10.1038/nrcardio.2013.220

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2013.220

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing